Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Kidney Medicine|July 26, 2023
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and CanadaJeffrey T Ha, Anish Scaria, Jason Andrade, et al.
JAMA|August 2, 2017
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Hong Zhang, Muh Geot Wong, et al.
Circulation|February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE TrialNan Ye, Meg J Jardine, Megumi Oshima, et al.
American Journal of Nephrology|November 3, 2021
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline CharacteristicsMuh Geot Wong, Jicheng Lv, Michelle A Hladunewich, et al.
JAMA|May 17, 2022
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Muh Geot Wong, Michelle A Hladunewich, et al.
Kidney International|October 1, 2025
Changing paradigms of studies in kidney diseasesAdeera Levin, Allison Jaure, Dustin J Little, et al.
The Lancet. Diabetes & Endocrinology|July 11, 2024
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M Apperloo, Brendon L Neuen, Robert A Fletcher, et al.
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
Pageof 24